Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information

American Journal of Transplantation

Volumn 15, Issue 9, 2015, Pages 2421-2430

  Tambur, A R ^a   Herrera, N D ^a   Haarberg, K M K ^a   Cusick, M F ^a   Gordon, R A ^a   Leventhal, J R ^a   Friedewald, J J ^a   Glotz, D ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Antibody biology; desensitization; major histocompatibility complex (MHC); rejection: antibody mediated (ABMR)

Indexed keywords

ANTIBODY; BORTEZOMIB; COMPLEMENT COMPONENT C1Q; DONOR SPECIFIC ANTIBODY; EDETIC ACID; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DRB1 ANTIGEN; UNCLASSIFIED DRUG; ALLOANTIBODY; HLA ANTIGEN;

ADULT; ALLELE; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; C1Q COMPLEMENT BINDING SOLID PHASE IMMUNOASSAY; COMPARATIVE STUDY; COMPLEMENT FIXATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DESENSITIZATION; FEMALE; FOLLOW UP; GENE LOCUS; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN G SOLID PHASE IMMUNOASSAY; IMMUNOLOGICAL PARAMETERS; INTERMETHOD COMPARISON; LUMINEX SINGLE ANTIGEN SOLID PHASE IMMUNOASSAY; MALE; MEAN FLUORESCENCE INTENSITY; MIDDLE AGED; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT DURATION; BLOOD; CASE REPORT; DONOR; FLUORESCENCE; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PROGNOSIS;

ADULT; ANTIBODY SPECIFICITY; COMPLEMENT C1Q; FEMALE; FLUORESCENCE; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; PROGNOSIS; TISSUE DONORS;

EID: 84939564869     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13295     Document Type: Article

References (26)

1. Tait BD, Susal C, Gebel HM, et al., Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47.
2. Marfo K, Ajaimy M, Colovai A, et al., Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies. Transplantation 2014; 98: 1082-1088.
3. Alachkar N, Lonze BE, Zachary AA, et al., Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012; 94: 165-171.
4. Zachary A, Reinsmoen NL,. Quantifying HLA-specific antibodies in patients undergoing desensitization. Curr Opin Organ Transplant 2011; 16: 410-415.
5. Lefaucheur C, Loupy A, Hill GS, et al., Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
6. Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D,. HLA antibody specification using single-antigen beads-a technical solution for the prozone effect. Transplantation 2011; 92: 510-515.
7. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB,. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012; 16: 12-17.
8. Tyan DB,. New approaches for detecting complement-fixing antibodies. Curr Opin Organ Transplant 2012; 17: 409-415.
9. Loupy A, Lefaucheur C, Vernerey D, et al., Complement-binding anti-HLA antibodies and kidney-allograft survival. New Engl J Med 2013; 369: 1215-1226.
10. Morrow WR, Frazier EA, Mahle WT, et al., Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 2012; 93: 319-324.
11. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J,. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant 2011; 30: 1320-1326.
12. Campbell P, Clinical relevance of human leukocyte antigen antibodies in liver, heart, lung and intestine transplantation. Curr Opin Organ Transplant 2013; 18: 463-469.
13. Susal C, Roelen DL, Fischer G, et al., Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients. Tissue Antigens 2013; 82: 83-92.
14. Chang D, Kobashigawa J,. The use of the calculated panel-reactive antibody and virtual crossmatch in heart transplantation. Curr Opin Organ Transplant 2012; 17: 423-426.
15. Zachary AA, Sholander JT, Houp JA, Leffell MS,. Using real data for a virtual crossmatch. Hum Immunol 2009; 70: 574-579.
16. Tambur AR, Ramon DS, Kaufman DB, et al., Perception versus reality?: Virtual crossmatch-how to overcome some of the technical and logistic limitations. Am J Transplant 2009; 9: 1886-1893.
17. Gebel HM, Bray RA,. HLA antibody detection with solid phase assays: Great expectations or expectations too great? Am J Transplant 2014; 14: 1964-1975.
18. Guidicelli G, Anies G, Bachelet T, et al., The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients. Transplant Immunol 2013; 29: 17-21.
19. Visentin J, Vigata M, Daburon S, et al., Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays. Transplantation 2014; 98: 625-631.
20. Schwaiger E, Wahrmann M, Bond G, Eskandary F, Bohmig GA,. Complement component C3 activation: The leading cause of the prozone phenomenon affecting HLA antibody detection on single-antigen beads. Transplantation 2014; 97: 1279-1285.
21. Zeevi A, Lunz J, Feingold B, et al., Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 2013; 32: 98-105.
22. Chen G, Sequeira F, Tyan DB,. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72: 849-858.
23. Everly MJ, Rebellato LM, Haisch CE, et al., Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410-417.
24. Kim JJ, Balasubramanian R, Michaelides G, et al., The clinical spectrum of de novo donor-specific antibodies in pediatric renal transplant recipients. Am J Transplant 2014; 14: 2350-2358.
25. Walsh RC, Brailey P, Girnita A, et al., Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011; 91: 1218-1226.
26. Diebolder CA, Beurskens FJ, de Jong RN, et al., Complement is activated by IgG hexamers assembled at the cell surface. Science 2014; 343: 1260-1263.